Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert L Atmar

Showing results (201-210 of 237) with videos related to

Pageof 24
Sort By:
Plos Neglected Tropical Diseases|March 30, 2023
A randomized, controlled Phase 1b trial of the Sm-TSP-2 Vaccine for intestinal schistosomiasis in healthy Brazilian adults living in an endemic areaDavid J Diemert, Rodrigo Correa-Oliveira, Carlo Geraldo Fraga, et al.
Vaccine|July 29, 2017
Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical TrialMark J Mulligan, Jack T Stapleton, Wendy A Keitel, et al.
JAMA|July 22, 2015
Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical TrialLisa A Jackson, James D Campbell, Sharon E Frey, et al.
Clinical and Vaccine Immunology : CVI|June 5, 2015
Serological Correlates of Protection against a GII.4 NorovirusRobert L Atmar, David I Bernstein, G Marshall Lyon, et al.
Open Forum Infectious Diseases|July 12, 2022
Unraveling the Treatment Effect of Baricitinib on Clinical Progression and Resource Utilization in Hospitalized COVID-19 Patients: Secondary Analysis of the Adaptive COVID-19 Treatment Randomized Trial-2Jonathan Fintzi, Tyler Bonnett, Pablo Tebas, et al.
MMWR. Morbidity and Mortality Weekly Report|February 24, 2022
Use of Ebola Vaccine: Expansion of Recommendations of the Advisory Committee on Immunization Practices To Include Two Additional Populations - United States, 2021Jason H Malenfant, Allison Joyce, Mary J Choi, et al.
The Journal of Infectious Diseases|January 26, 2023
A Multicenter, Controlled Human Infection Study of Influenza A(H1N1)pdm09 in Healthy AdultsJustin R Ortiz, David I Bernstein, Daniel F Hoft, et al.
Open Forum Infectious Diseases|April 18, 2022
Association of Secretor Status and Recent Norovirus Infection With Gut Microbiome Diversity Metrics in a Veterans Affairs PopulationJordan A Johnson, Timothy D Read, Robert A Petit, et al.
MMWR. Morbidity and Mortality Weekly Report|May 31, 2019
Hurricane-Associated Mold Exposures Among Patients at Risk for Invasive Mold Infections After Hurricane Harvey - Houston, Texas, 2017Nancy A Chow, Mitsuru Toda, Audrey F Pennington, et al.
Vaccine|February 25, 2026
The safety, reactogenicity, and immunogenicity of the self-amplifying mRNA COVID-19 vaccine GRT-R910 as a booster in healthy adultsJennifer A Whitaker, Paulina A Rebolledo, Getahun Abate, et al.
Pageof 24

Showing results (201-210 of 237) with videos related to

Sort By:
Pageof 24
Plos Neglected Tropical Diseases|March 30, 2023
A randomized, controlled Phase 1b trial of the Sm-TSP-2 Vaccine for intestinal schistosomiasis in healthy Brazilian adults living in an endemic areaDavid J Diemert, Rodrigo Correa-Oliveira, Carlo Geraldo Fraga, et al.
Vaccine|July 29, 2017
Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical TrialMark J Mulligan, Jack T Stapleton, Wendy A Keitel, et al.
JAMA|July 22, 2015
Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical TrialLisa A Jackson, James D Campbell, Sharon E Frey, et al.
Clinical and Vaccine Immunology : CVI|June 5, 2015
Serological Correlates of Protection against a GII.4 NorovirusRobert L Atmar, David I Bernstein, G Marshall Lyon, et al.
Open Forum Infectious Diseases|July 12, 2022
Unraveling the Treatment Effect of Baricitinib on Clinical Progression and Resource Utilization in Hospitalized COVID-19 Patients: Secondary Analysis of the Adaptive COVID-19 Treatment Randomized Trial-2Jonathan Fintzi, Tyler Bonnett, Pablo Tebas, et al.
MMWR. Morbidity and Mortality Weekly Report|February 24, 2022
Use of Ebola Vaccine: Expansion of Recommendations of the Advisory Committee on Immunization Practices To Include Two Additional Populations - United States, 2021Jason H Malenfant, Allison Joyce, Mary J Choi, et al.
The Journal of Infectious Diseases|January 26, 2023
A Multicenter, Controlled Human Infection Study of Influenza A(H1N1)pdm09 in Healthy AdultsJustin R Ortiz, David I Bernstein, Daniel F Hoft, et al.
Open Forum Infectious Diseases|April 18, 2022
Association of Secretor Status and Recent Norovirus Infection With Gut Microbiome Diversity Metrics in a Veterans Affairs PopulationJordan A Johnson, Timothy D Read, Robert A Petit, et al.
MMWR. Morbidity and Mortality Weekly Report|May 31, 2019
Hurricane-Associated Mold Exposures Among Patients at Risk for Invasive Mold Infections After Hurricane Harvey - Houston, Texas, 2017Nancy A Chow, Mitsuru Toda, Audrey F Pennington, et al.
Vaccine|February 25, 2026
The safety, reactogenicity, and immunogenicity of the self-amplifying mRNA COVID-19 vaccine GRT-R910 as a booster in healthy adultsJennifer A Whitaker, Paulina A Rebolledo, Getahun Abate, et al.
Pageof 24